This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Zhejiang Doer Biologics Co., Ltd.. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: Changkui Li: Innovator in Anti-CLD18A2 VHH Development
Introduction
Changkui Li is a prominent inventor based in Hangzhou, China. He has made significant contributions to the field of biology, particularly in the development of heavy-chain antibodies. His innovative work focuses on creating specific antibodies that can target cancer-related proteins.
Latest Patents
Changkui Li holds a patent for "Heavy-chain antibodies (VHHs) against claudin 18A2 and use thereof." This patent describes an anti-CLD18A2 VHH that includes complementarity determining regions (CDRs) with specific amino acid sequences. The anti-CLD18A2 VHH can bind specifically to the epitope on CLD18A2, demonstrating good specificity and affinity. This innovation has shown a noticeable tumor suppression effect, highlighting its potential in cancer treatment.
Career Highlights
Throughout his career, Changkui Li has worked with notable companies, including Zhejiang Doer Biologics Co., Ltd. and Zhejiang Doer Biologics Corporation. His experience in these organizations has contributed to his expertise in biotechnological innovations.
Collaborations
Changkui Li has collaborated with esteemed colleagues such as Gaofeng Yao and Yali Lu. These partnerships have further enhanced his research and development efforts in the field of biology.
Conclusion
Changkui Li's work in developing anti-CLD18A2 VHHs represents a significant advancement in cancer research. His innovative approach and collaborations have the potential to impact the future of cancer therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile